Quantcast

Latest Exenatide Stories

2014-08-30 23:02:07

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New York, New York (PRWEB) August 30, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in U.S. courts, Bernstein Liebhard LLP reports. According to a statement issued by AstraZeneca PLC on July 31, 2014, Byetta and Bydureon (an extended-release...

2014-08-15 23:00:59

The Firm is actively investigating Januvia and Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and other serious injuries after taking either of the diabetes treatments. New York, NY (PRWEB) August 15, 2014 Healthcare regulators in British Columbia have stopped patient coverage of a diabetes drug now involved in hundreds of Byetta lawsuits (http://www.byettalawsuit.com/) as well as several other medications, Bernstein Liebhard LLP reports....

diabetes drug metformin
2014-08-11 04:19:36

April Flowers for redOrbit.com - Your Universe Online A large-scale study from Cardiff University, involving over 180,000 people, reveals that people with Type 2 diabetes can live longer than those without the condition, thanks to a widely prescribed blood glucose control medication. The findings, published in Diabetes, Obesity and Metabolism, suggest that metformin — commonly used to control glucose levels in the body and known for exhibiting anticancer properties — could offer...

2014-08-10 23:01:12

The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid cancer. New York, New York (PRWEB) August 10, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, such as Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District...

2014-08-05 08:35:45

- Zalani joins Intarcia to drive the strategic and operational direction of Intarcia's Global Regulatory and Quality efforts with health authorities, partners and external stakeholders - BOSTON, Aug. 5, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of Regulatory Affairs and Quality. In her new capacity, Dr. Zalani serves on the Leadership Team and reports directly to Chairman,...

2014-07-17 04:21:04

MT Services LLC informs plaintiffs on various pharmaceutical drug cases available to obtain lawsuit funding and legal assistance BRONX, N.Y., July 17, 2014 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company, which operates lawsuitsettlementnews.com announced today a primary focus on assisting plaintiffs of bad pharmaceutical drugs such as AndgroGel: Testosterone Creams, Accutane, Acetaminophen, Actos, Avandia, Byetta-Januvia-Victoza, Birth Control Products:...

2014-07-05 23:01:25

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer, due to their use of the Type 2 diabetes medication. New York, NY (PRWEB) July 05, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to...

2014-06-27 04:21:25

Pre-Settlement Case Funding Firm announces new program focus for plaintiffs of Byetta, as well as Actos, Januvia, and Victoza cases. LOS ANGELES, June 27, 2014 /PRNewswire/ -- Legal-Bay LLC, the Lawsuit Settlement Funding Company, disclosed today a new lawsuit cash advance program that helps clients with cases facing Byetta complications. In 2011, after California medical researchers discovered that patients using Byetta are 3 times more at risk for Pancreatic cancer, the number of...

2014-06-19 04:21:32

Pre-Settlement Case Funding Firm announces new program focus for plaintiffs who used Actos, as well as Byetta, Januvia, and Victoza NEW ORLEANS, June 19, 2014 /PRNewswire/ -- Legal-Bay LLC, the Lawsuit Settlement Funding Company, disclosed today a new-implemented program involving lawsuit cash advances for clients facing complications due to risky Actos prescription drugs. In April 2014, Terrence and Susan Allen were awarded $9 billion from the Louisiana jury in the first official...

2014-06-15 08:21:29

-- The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels between 10-12%. BOSTON, June 15, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial...


Latest Exenatide Reference Libraries

36_67c6fec75293d7e1e91a0c52aa692cf7
2005-06-22 14:17:05

The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...

More Articles (1 articles) »
Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related